Most-Favored-Nation (MFN) drug pricing sounds simple on paper: tie what the U.S. pays for certain drugs to the lowest price available in comparable countries. And the motivation is real. In 2022, U.S. prescription drug prices were 2.78× those in 33 other OECD countries; for brand-name drugs, U.S. prices were more than 3× higher. The U.S. also represented 62% of sales but only 24% of volume across the countries studied—an illustration of how “price” (not just utilization) drives U.S. spending.
A concrete example: for semaglutide (Ozempic), the U.S. list price for one month (~$936) has been estimated at ~5× Japan and ~10× several peer nations including France, the U.K., Sweden, and Australia.
Where MFN is Headed
MFN isn’t a single statute; it’s a policy approach that can be implemented through different vehicles. A major recent U.S. move was a May 2025 executive order directing the administration to pursue MFN-style pricing, followed by HHS stating it would set drug-pricing “targets” pegged to the lowest price paid by certain OECD countries, using a comparability screen (OECD countries with GDP per capita ≥ 60% of U.S. GDP per capita).
In theory, these measures should lower costs without directly limiting access. In practice, clinicians rarely experience policy changes as tidy abstractions. They feel them as shifting formularies, new prior authorization hoops, and unexpected pharmacy callbacks.
This also builds on earlier federal efforts. For example, CMS’s Innovation Center previously described an MFN “Model” concept for Medicare Part B drugs that would have linked payment to the lowest price in comparable OECD countries (also using a GDP-per-capita threshold). Even when announced, MFN implementation details and timelines can shift because operational design, contracting behavior, and litigation risk tend to determine what actually reaches the bedside.
The theory is clean. The clinical reality usually isn’t.
For many clinicians, the first sign that MFN-related changes are in play is a familiar scenario: a patient who has been stable on a therapy for months suddenly learns it is no longer covered or requires new documentation. The explanation may be buried in payer policy updates that link reimbursement levels to international reference prices. Patients understandably perceive this as arbitrary or even punitive, when in reality it is a downstream effect of a broad pricing experiment.
Coverage volatility is the real clinical challenge. As payers respond to MFN benchmarks, they may tighten criteria, favor certain alternatives, or reclassify drugs into higher-cost tiers. Formularies can churn mid-year, forcing clinicians to spend time justifying previously approved therapies. Even small changes in documentation requirements can delay care in meaningful ways, especially in oncology, rheumatology, and other specialties reliant on high-cost agents. We already know that for nearly every physician, prior authorizations have led to reported delays in patient care.
The patient trust problem (and how to blunt it)
From a patient’s perspective, these shifts can erode trust. Someone who has been told, “This is the right medication for you,” may feel confused or abandoned when access suddenly changes. Clear communication helps. Clinicians don’t have to defend the policy to preserve trust; they only need to clarify agency and advocacy:
“Your insurance is changing how they cover this drug. My recommendation hasn’t changed—let’s work together on the best next step.”
That single reframing often prevents patients from interpreting a payer rule as a reversal in clinical judgment.
Practical steps clinicians can take now
- Identify “high-friction” meds (oncology, rheumatology, complex biologics) and run scheduled benefit checks rather than waiting for the refill crisis.
- Build a tighter loop with specialty pharmacies and in-house PA teams so documentation is standardized and reusable.
- Create “fast paths” for appeals and peer-to-peer workflows—especially for stable patients facing mid-course disruptions.
- Maintain an updated playbook for therapeutic alternatives, patient assistance programs, and foundation support when clinically appropriate.
Bottom line
MFN pricing may reduce overall spending, but the route there is unlikely to be smooth. For clinicians, the core risk isn’t the headline price benchmark, it’s the operational response: coverage churn, tighter criteria, and more administrative friction. The best defense is staying alert to early signals, building workflows that anticipate volatility, and communicating in a way that keeps patients confident their clinician is still in their corner, even when the system feels unpredictable.